Wilmington, DE, United States of America

Incyte Incorporation

Calculating rank
USPTO Granted Patents = 4

% Expired Patents = 25.0

Forward Citations = 16

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Jincong Zhuo (1 out of 76 patents)

silverMedal Wenqing Yao (1 out of 228 patents)

bronzeMedal Chunhong He (1 out of 73 patents)

4.  Stacey Shepard (1 out of 59 patents)

5.  Lei Qiao (1 out of 21 patents)

6.  Jiacheng Zhou (1 out of 86 patents)

7.  Yongchun Pan (1 out of 40 patents)

8.  Lingkai Weng (1 out of 15 patents)

9.  Pingli Liu (1 out of 37 patents)

10.  Jack Guoen Shi (1 out of 3 patents)

11.  Phillip R Hawkins (1 out of 78 patents)

12.  Craig G Wilde, Deceased (1 out of 1 patent)

13.  Jeffrey J Seilhamer, Deceased (1 out of 1 patent)

14.  James David Rodgers (1 out of 86 patents)

15.  Argyrios George Arvanitis (1 out of 24 patents)


4 patents:

Company Overview
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to meet the critical needs of patients. The company's research and development efforts are primarily focused on oncology and inflammation. Incyte is dedicated to advancing medical science in order to improve the lives of patients worldwide.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

4 Patents

#619 in Wilmington, DE

#863 in Delaware

#60,778 in US

Wilmington, DE (US)
Wilmington, DE, United States of America
Forward Citations = 16

16 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Incyte Incorporation. Retrieved from https://idiyas.com/company/incyte-in

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…